Revolutionizing the Management of Your Patients With CKD at Risk of Progression, With or Without T2D
Sponsored by AstraZeneca
This webinar is educational in nature, however, no CPEUs will be offered.
INVITE A FRIEND! This webinar is available to ALL ACADEMY MEMBERS for FREE. Please share with others outside of our DPG who may benefit.
It is estimated that ~37 million US adults or approximately 1 in 7 adults have chronic kidney disease (CKD). Furthermore, this common diabetes complication is often undiagnosed in those with type 2 diabetes. Join us for this webinar, which will explore the progressive nature of CKD and the importance of early screening and diagnosis. SGLT2 inhibitors are the first treatment in 20 years to slow the progression of CKD in patients with type 2 diabetes and also in patients with hypertension. Our speaker will discuss these new treatment options for your patients and supporting data from the DAPA-CKD trial.
Presented on: Tuesday December 7, 2021 at 1 pm CT, 2 pm ET
Maria O'Connor, PA-C, RD, CDCES
Maria O’Connor PA-C, RD, CDCES is a Certified Physician Assistant, Registered Dietitian and Certified Diabetes Care Education Specialist. Maria joined Astra Zeneca as Sr. Medical Science Liaison in their Cardiovascular and Metabolic Medical Affairs division in 2014. Previously she was an endocrinology PA for 10 years at Rush University in Chicago, IL. Aside from her direct patient care role; she was involved in research studies for children and adolescents with Type 2 diabetes and the education of physician assistant students at Rush University and Midwestern as a preceptor. Prior to that, she worked for 4 years as a registered dietitian with an emphasis in working with patients with end stage renal disease and diabetes.
She graduated with Physician Assistant Certification from Cook County Hospital in Chicago, IL, her Masters of Science in Nutrition from Southern Illinois University in Carbondale, IL and her Bachelors of Science from Purdue University in West Lafayette, IN. Maria currently lives in Chicago, IL with her husband, son and 2 daughters.
1. Describe the progressive nature of CKD and its link to significant
mortality and morbidity.
2. Highlight the importance of screening and diagnosis for CKD.
3. Discuss new treatment options for patients with CKD and T2D and supporting data from the DAPA-CKD trial.
Access Webinar Here
Not a DDPG DPG member? The investment in DDPG membership will pay for itself if you attend just one webinar! With DDPG membership you receive ~15 CEUs throughout the membership year (with Webinars and through “On the Cutting Edge”) approximately $2/ CEU!
Why not join today and significantly reduce the cost of CEUs without the expense of traveling?